metricas
covid
Buscar en
Actas Urológicas Españolas (English Edition)
Toda la web
Inicio Actas Urológicas Españolas (English Edition) Prevalence of urinary tract cancer in the Spanish cohort of the IDENTIFY study
Journal Information
Vol. 48. Issue 3.
Pages 228-237 (April 2024)
Share
Share
Download PDF
More article options
Visits
3
Vol. 48. Issue 3.
Pages 228-237 (April 2024)
Original article
Prevalence of urinary tract cancer in the Spanish cohort of the IDENTIFY study
Prevalencia del cáncer del tracto urinario. Análisis de la cohorte española del estudio IDENTIFY
Visits
3
C. Toribio-Vázqueza,b,
Corresponding author
carlost@uic.es

Corresponding author.
, J. Gómez Rivasc, F. Amigod, D.M. Carrióna, Á. Yebesa, M. Alonso-Bartoloméa, H. Ayllona, A. Aguileraa,b, L. Martinez-Piñeiroa, M. Antón-Juanillae, V. Crespo-Atíne, H. Otaola-Arcae, J.A. Herranz-Yaguee, M.V. Munoz Riveroe, K.R. MacKenziee, T.T. Shahe, C. Gaoe, E. Zimmermanne, M. Jefferiese, A. Nambiare..., K.M. Gallaghere, S. Khadhourie, V. Kasivisvanathane, IDENTIFY Study group 1Ver más
a Servicio de Urología, Hospital Universitario La Paz, Madrid, Spain
b Universidad Autónoma de Madrid, Madrid, Spain
c Servicio de Urología, Hospital Universitario Clínico San Carlos, Madrid, Spain
d Institut Hospital del Mar d''Investigacions Mèdiques, Barcelona, Spain
e IDENTIFY Study group
This item has received
Article information
Abstract
Full Text
Bibliography
Download PDF
Statistics
Tables (4)
Table 1. Patient demographics and clinical characteristics of the Spanish cohort, according to the presence or absence of cancer, and type of cancer.
Table 2. Proportion of cancers according to age, sex and smoking habits, stratified by type of hematuria.
Table 3. Adjusted and unadjusted cancer prevalence estimates by type of hematuria and cancer.
Table 4. Association of risk markers with prevalence of urinary tract cancers.
Show moreShow less
Additional material (1)
Abstract
Introduction

Malignant tumors of the urinary tract are associated with high morbidity and mortality, and their prevalence can vary worldwide. Recently, the IDENTIFY study has published results on the prevalence of urinary tract cancer at a global level. This study evaluates the prevalence of cancer within the Spanish cohort of the IDENTIFY study to determine whether the published results can be extrapolated to our population.

Patients and methods

An analysis of the data from the Spanish cohort of patients in the IDENTIFY study was performed. This is a prospective cohort of patients referred to secondary care with suspected cancer, predominantly due to hematuria. Patients were recruited between December 2017 and December 2018.

Results

A total of 706 patients from 9 Spanish centers were analyzed. Of these, 277 (39.2%) were diagnosed with cancer: 259 (36.7%) bladder cancer, 10 (1.4%) upper tract urothelial carcinoma, 9 (1.2%) renal cancer and 5 (0.7%) prostate cancer. Increasing age (OR 1.05 (95% CI 1.03−1.06; P < 0.001)), visible hematuria (VH) OR 2.19 (95% CI 1.13–4.24; P = 0.02)) and smoking (ex-smokers: OR 2.11(95% CI 1.30–3.40; P = 0.002); smokers: OR 2.36 (95% CI 1.40–3.95; P = 0.001)) were associated with higher probability of bladder cancer.

Conclusion

This study highlights the risk of bladder cancer in patients with VH and smoking habits. Bladder cancer presented the highest prevalence; higher than the prevalence reported in previous series and presented in the IDENTIFY study. Future work should evaluate other associated factors that allow us to create cancer prediction models to improve the detection of cancer in our patients.

Keywords:
Hematuria
Urinary tract cancer
Urothelial carcinoma
Bladder cancer
Renal cancer
Risk factors
Resumen
Introducción

Los tumores malignos del tracto urinario están asociados a gran morbilidad y mortalidad siendo su prevalencia variable a nivel global. Recientemente el estudio IDENTIFY ha publicado resultados sobre la prevalencia del cáncer del tracto urinario a nivel internacional. Este estudio evalúa la prevalencia de cáncer dentro de la cohorte española del estudio IDENTIFY para determinar si los resultados publicados son extrapolables a nuestra población.

Material y métodos

Se realizo un análisis de los datos de la cohorte de pacientes españoles del estudio IDENTIFY. Se trata de una cohorte prospectiva de pacientes derivados al hospital con sospecha de cáncer, predominantemente por hematuria. Los pacientes fueron reclutados entre diciembre de 2017 y diciembre de 2018.

Resultados

En total 706 pacientes procedente de 9 centros españoles fueron analizados. 277(39,2%) fueron diagnosticados de cáncer, 259(36.7%) cáncer vejiga, 10(1.4%) tracto urinario superior, 9 (1.2%) renal y 5 (0.7%) próstata. El aumento de la edad (OR 1,05(95%CI 1,03−1,06;<0,001)), presencia de hematuria visible OR 2,19(95%CI1,13−4,24;P = 0,02)) y el hábito tabáquico (exfumadores:OR2,11(95%CI1,30−3,40;P = 0,002); fumadores:OR2,36(95%CI 1,40−3,95;P = 0,001)) se asocia con mayor probabilidad de cáncer vesical.

Conclusión

Este estudio resalta el riesgo que existe en pacientes con HV y habito tabáquico de presentar cáncer de vejiga. El cáncer de vejiga presentó la mayor prevalencia, siendo esta mayor que la expuesta en series previas y la presentada en el estudio IDENTIFY. Trabajos futuros deben evaluar otros factores asociados que permitan crear modelos de predicción de cáncer para seguir aumentando la detección de estos en nuestros pacientes.

Palabras clave:
Hematuria
Cáncer del tracto urinario
Carcinoma urotelial
Cáncer vesical
Cáncer renal
Factores de riesgo

Article

These are the options to access the full texts of the publication Actas Urológicas Españolas (English Edition)
Subscriber
Subscriber

If you already have your login data, please click here .

If you have forgotten your password you can you can recover it by clicking here and selecting the option “I have forgotten my password”
Subscribe
Subscribe to

Actas Urológicas Españolas (English Edition)

Purchase
Purchase article

Purchasing article the PDF version will be downloaded

Price 19.34 €

Purchase now
Contact
Phone for subscriptions and reporting of errors
From Monday to Friday from 9 a.m. to 6 p.m. (GMT + 1) except for the months of July and August which will be from 9 a.m. to 3 p.m.
Calls from Spain
932 415 960
Calls from outside Spain
+34 932 415 960
E-mail
Article options
es en pt

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos

Quizás le interese:
10.1016/j.acuroe.2022.01.005
No mostrar más